Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression

Neuropsychobiology

Volumn 65, Issue 2, 2012, Pages 70-75

  Serretti, Alessandro ^a   Chiesa, Alberto ^a   Crisafulli, Concetta ^b   Massat, Isabelle ^c   Linotte, Sylvie ^d   Calati, Raffaella ^a   Kasper, Siegfried ^e   Bailer, Ursula ^e   Lecrubier, Yves ^f   Fink, Martin ^e   Antonijevic, Irina ^g   Forray, Carlos ^g   Snyder, Lenore ^g   Bollen, Joseph ^h   Zohar, Joseph ⁱ   De Ronchi, Diana ^a   Souery, Daniel ^d   Mendlewicz, Julien ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c FNRS   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g LUNDBECK RESEARCH USA   (United States)

^h Sint Truiden Psychiatric Center   (Belgium)

ⁱ SHEBA MEDICAL CENTER   (Israel)

Author keywords

GNB3; GRIK4; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GNB 3 GENE; GRIK 4 GENE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, KAINIC ACID; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84855389473     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000329553     Document Type: Article

References (24)

1. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB: Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010; 35: 727-740.
2. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR * D cohort. Am J Psychiatry 2007; 164: 1181-1188. (Pubitemid 47292406)
3. Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, Lu RB: Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1167-1172.
4. Wilkie MJ, Smith D, Reid IC, Day RK, Matthews K, Wolf CR, Blackwood D, Smith G: A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 2007; 17: 207-215. (Pubitemid 46668005)
5. Serretti A, Lorenzi C, Cusin C, Zanardi R, Lattuada E, Rossini D, Lilli R, Pirovano A, Catalano M, Smeraldi E: SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol 2003; 13: 117-122. (Pubitemid 36313286)
6. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B: Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000; 11: 1893-1897. (Pubitemid 30429131)
7. Lee HJ, Cha JH, Ham BJ, Han CS, Kim YK, Lee SH, Ryu SH, Kang RH, Choi MJ, Lee MS: Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 2004; 4: 29-33.
8. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Agedependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339-346. (Pubitemid 38146251)
9. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP: Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67: 1110-1113.
10. Kang RH, Hahn SW, Choi MJ, Lee MS: Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 2007; 56: 1-5.
11. Hong CJ, Chen TJ, Yu YW, Tsai SJ: Response to fluoxetine and serotonin 1a receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006; 6: 27-33. (Pubitemid 43118308)
12. Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A: Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1041-1044. (Pubitemid 351609242)
13. Bishop JR, Ellingrod VL, Moline J, Miller D: Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006; 12:BR47-BR50. (Pubitemid 43200936)
14. Rodriguez-Moreno A, Sihra TS: Metabotropic actions of kainate receptors in the CNS. J Neurochem 2007; 103: 2121-2135. (Pubitemid 350173562)
15. Hamm HE: The many faces of G protein signaling. J Biol Chem 1998; 273: 669-672. (Pubitemid 28049148)
16. Keers R, Bonvicini C, Scassellati C, Uher R, Placentino A, Giovannini C, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W, Hauser J, Souery D, Mendlewicz J, Schmal C, Zobel A, Larsen ER, Szczepankiewicz A, Kovacic Z, Elkin A, Craig I, McGuffin P, Farmer AE, Aitchison KJ, Gennarelli M: Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol E-pub ahead of print.
17. Kraft P: Curses-winner's and otherwise-in genetic epidemiology. Epidemiology 2008; 19: 649-651; discussion 657-648.
18. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J: Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007; 68: 1062-1070. (Pubitemid 47340327)
19. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D: Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009; 24: 250-256.
20. Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J: A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 2011; 128: 56-63.
21. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
22. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, Lawrence Erlbaum Associates, 1988.
23. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, Lewis S, Birney E, Stein L: Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 2005; 33:D428-D432. (Pubitemid 40207909)
24. Posternak MA, Zimmerman M: How accurate are patients in reporting their antidepressant treatment history? J Affect Disord 2003; 75: 115-124. (Pubitemid 36645244)